Buyside wrestles with OTC derivatives valuation
Buyside participants, in particular insurance firms and pension schemes, have not adequately invested in risk management infrastructure and are not pricing their derivatives exposures or collateral charges effectively in light of new rules and accounting standards.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
